Is IDYA a good stock to buy? We came across a bullish thesis on IDEAYA Biosciences, Inc. on Valueinvestorsclub.com by pestopenguin. In this article, we will summarize the bulls’ thesis on IDYA. IDEAYA Biosciences, Inc.’s share was trading at $29.48 as of April 27th. IDYA’s forward P/E was 4.65 according to Yahoo Finance.
Tonhom1009/Shutterstock.com
Ideaya Biosciences is positioned as a catalyst-rich precision oncology company as investors focus on the upcoming Phase II–III OptimUM-02 readout for darovasertib in first-line HLA-A2-negative metastatic uveal melanoma in 1Q 2026, which represents a pivotal de-risking event for its lead program.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Darovasertib, a PKC inhibitor partnered with crizotinib, targets GNAQ/GNA11-driven signaling through dual MAPK and c-MET pathway suppression, and prior Phase 1–2 OptimUM-01 data demonstrated approximately 7-month median progression-free survival and 21-month overall survival with a favorable safety profile versus standard therapies.
Importantly, the pivotal study compares against investigator’s choice therapies where historical progression-free survival is around three months, meaning a modest ~5.5-month threshold could be sufficient for statistical success, while competitive benchmark Kimmtrak reinforces the commercial validity of the indication.
With over 90% of patients harboring GNAQ or GNA11 mutations, the first-line HLA-A2-negative metastatic uveal melanoma market represents roughly $300 million in near-term revenue potential and expands toward a broader $1.6 billion opportunity across treatment lines, further supported by orphan and breakthrough designations that strengthen regulatory visibility.
Ideaya maintains a strong balance sheet with approximately $1.1 billion in cash providing runway into 2030, supplemented by a $210 million upfront Servier partnership with additional milestones and cost-sharing, significantly reducing near-term dilution risk.
Overall, the upcoming readout represents a high-probability catalyst to validate darovasertib’s mechanism, potentially supporting accelerated approval and meaningful rerating of Ideaya Biosciences, with base-case scenarios implying strong upside and favorable risk-reward skew versus current market expectations and limited downside given de-risked clinical profile and improving sentiment expected ahead.
Previously, we covered a bullish thesis on Moderna, Inc. (MRNA) by YouAlwaysHaveAChoice in February 2025, which highlighted infectious disease catalysts, institutional accumulation, and technical bullish signals. MRNA’s stock price has appreciated by approximately 46.33% since our coverage. pestopenguin shares a similar view but emphasizes Ideaya Biosciences’ upcoming clinical catalyst, strong balance sheet, and de-risked oncology pipeline driving asymmetric upside in biotech.
IDEAYA Biosciences, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held IDYA at the end of the fourth quarter which was 39 in the previous quarter. While we acknowledge the risk and potential of IDYA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IDYA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
